Inventor · disambiguated record
Petrus Johannes Simons
Also filed as: SIMONS PETRUS J · SIMONS PETRUS JOHANNES
7 granted patents·5 pending applications·39 citations·filing 2004–2021
83Inventor score
Files withBIOCEROX PROD BV5JJP BIOLOGICS SP Z O O3BROTEIO PHARMA B V2BOON LOUIS1SIMONS PETRUS JOHANNES1
Top patents by PatentIndex Score
12 records- 0185US9790281B2Humanized anti-CD134 (OX40) antibodies and uses thereofBIOCEROX PROD BV·Filed 2014·Granted Oct 17, 2017·10 cites·7 claims
- 0285US9475880B2Anti-CD134 (OX40) antibodies and uses thereofSIMONS PETRUS JOHANNES·Filed 2012·Granted Oct 25, 2016·14 cites·14 claims
- 0383US10717785B2Binding molecules that bind human complement factor C2 and uses thereofBROTEIO PHARMA B V·Filed 2018·Granted Jul 21, 2020·4 cites·20 claims
- 0479US10273307B2Humanized anti-CD134 (OX40) antibodies and uses thereofBIOCEROX PROD BV·Filed 2017·Granted Apr 30, 2019·3 cites·17 claims
- 0579US9944717B2Binding molecules that bind human complement factor C2 and uses thereofBROTEIO PHARMA B V·Filed 2014·Granted Apr 17, 2018·7 cites·15 claims
- 0673US12195539B2Anti-human CD89 antibodies and uses thereofJJP BIOLOGICS SP Z O O·Filed 2019·Granted Jan 14, 2025·1 cites·28 claims
- 0754US2019202928A1Humanized Anti-CD134 (OX40) Antibodies And Uses ThereofBIOCEROX PROD BV·Filed 2019·Application pending·0 cites
- 0853US2005214871A1Methods for using the CD163 pathway for modulating an immune responseBOON LOUIS·Filed 2004·Application pending·0 cites
- 0952US2018273632A1Anti-cd134 (ox40) antibodies and uses thereofBIOCEROX PROD BV·Filed 2018·Application pending·0 cites
- 1048US2023242646A1Humanized Anti-Human CD89 Antibodies and Uses ThereofJJP BIOLOGICS SP Z O O·Filed 2021·Application pending·0 cites
- 1147US12503516B2Anti-human HVEM (TNFRSF14) antibodies and uses thereofJJP BIOLOGICS SP Z O O·Filed 2020·Granted Dec 23, 2025·0 cites·17 claims
- 1247US2017051069A1Anti-cd134 (ox40) antibodies and uses thereofBIOCEROX PROD BV·Filed 2016·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →